Combination Treatment of Gemcitabine and Sorafenib Exerts a Synergistic Inhibitory Effect on Non‑small Cell Lung Cancer In�vitro and In�vivo via the Epithelial‑to‑mesenchymal Transition Process

Oncology Letters - Greece
doi 10.3892/ol.2020.11536
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Combination Studies With Gemcitabine in the Treatment of Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

Clinicopathological Significance of KAI1 Expression and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

World Journal of Surgical Oncology
SurgeryOncology
2015English

Non-Small Cell Lung Cancer Cells Survived Ionizing Radiation Treatment Display Cancer Stem Cell and Epithelial-Mesenchymal Transition Phenotypes

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2013English

Commentary on “Gemcitabine: Single‐Agent and Combination Therapy in Non‐Small Cell Lung Cancer”

Oncologist
Cancer ResearchMedicineOncology
1999English

Mechanism of Epithelial‑mesenchymal Transition Inhibited by miR‑203 in Non‑small Cell Lung Cancer

Oncology Reports
MedicineCancer ResearchOncology
2019English

Combination of Celecoxib and PD184161 Exerts Synergistic Inhibitory Effects on Gallbladder Cancer Cell Proliferation

Oncology Letters
Cancer ResearchOncology
2017English

GLUT3 Is Induced During Epithelial-Mesenchymal Transition and Promotes Tumor Cell Proliferation in Non-Small Cell Lung Cancer

Cancer & Metabolism
2014English

VEGFC/VEGFR3 Axis Mediates TGFβ1-induced Epithelial-To-Mesenchymal Transition in Non-Small Cell Lung Cancer Cells

PLoS ONE
Multidisciplinary
2018English

Refractory Non-Small-Cell Lung Cancer Responding to Combination Chemotherapy With Gemcitabine and Cisplatin

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy